Fast Five Quiz: Spinal Muscular Atrophy in Adults

Stephen L. Nelson, Jr, MD, PhD

Disclosures

February 01, 2021

Nusinersen, onasemnogene abeparvovec, and risdiplam are the only agents that have been approved for the treatment of SMA to date, but only nusinersen and risdiplam are approved for use in adult patients. Nusinersen is approved for all types of SMA, whereas risdiplam — which is taken orally — is approved for SMA types 1, 2 and 3.

Clinical data suggest nusinersen can be safely administered to adults with SMA with clinically meaningful benefits. In a recent retrospective review, the clinical benefits achieved with nusinersen in adults appeared to be cumulative over time. However, a high degree of variability in therapeutic response has also been observed, highlighting the need for biomarkers to better stratify patients to SMA treatments. Risdiplam has also shown encouraging results in adults with SMA.

Learn more about the treatment of SMA.

Editor's Recommendations

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....